TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05069519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook Health Education
Description: Participants assigned to this condition will receive a Fitbit smartwatch, continue with standard care, but will receive health education tips developed in the investigators' previous studies from a private Facebook group in which only group members and researchers can access. Additionally, the investigators will track login counts, analyze their post activity and online sentiments via texting mining and natural language processing, and then offer weekly personalized feedback based on the data to facilitate social support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook Health Education
Description: Participants assigned to this condition will receive a Fitbit smartwatch, continue with standard care, but will receive health education tips developed in the investigators' previous studies from a private Facebook group in which only group members and researchers can access. Additionally, the investigators will track login counts, analyze their post activity and online sentiments via texting mining and natural language processing, and then offer weekly personalized feedback based on the data to facilitate social support
Study: NCT05719337

Intervention type: DEVICE
Intervention: Echocardiography
Description: Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software.

Intervention type: DEVICE
Intervention: Echocardiography
Description: Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software.

Intervention type: DEVICE
Intervention: Echocardiography
Description: Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software.

Intervention type: DEVICE
Intervention: Echocardiography
Description: Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software.
Study: NCT06267209

Intervention type: OTHER
Intervention: Observational group
Description: After confirming that the patients not meet any of the exclusion criteria, dependent and confounding study variables will be assessed.~Patients will be recruited in 3 regions of Spain (Galicia, Madrid and Malaga), through the respective provincial associations and the Spanish Federation of Hemophilia.~The assessment will take place at the premises of the hemophilia associations included in the study. All the evaluations will be carried out by the same physiotherapist, following the same evaluation protocol.~The primary variable of the study will be the conditioned modulation of pain, being age the dependent variable. Secondary variables, estimated as modifiers or confounders, will be kinesiophobia, catastrophizing, anxiety perception, joint damage, pain intensity, functional capacity and pain threshold to pressure, and type of treatment and development of inhibitors.
Study: NCT04719611

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Healthy women receive a probiotic supplement containing 6 x 10\^9 colony-forming units/capsule of Bifidobacterium and Lactobacillus strains.
Study: NCT05575102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Football
Description: Walking Football (Soccer): Typical football rules apply but without running.~Participants will play at a local sports hall for 6-weeks, (2-hour per week). Time will be split between warm-up, football practice drills, and small-sided games.
Study: NCT04755647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide-Releasing Solution
Description: Active antimicrobial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution, hypotonic
Description: Placebo
Study: NCT04869761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion
Description: Single MSC infusion of 150x10\^6 cells at time zero; intravenous delivery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions
Description: Two MSC infusions of 75x10\^6 cells at time zero and three months; intravenous delivery
Study: NCT06328712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EN001
Description: * Cohort 1: EN001 1.25×10\^6 cells/kg administered intravenously (IV) 2 times at 4 week intervals.~* Cohort 2: EN001 2.5×10\^6 cells/kg administered intravenously (IV) 2 times at 4 week intervals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EN001
Description: * Cohort 1: EN001 1.25×10\^6 cells/kg administered intravenously (IV) 2 times at 4 week intervals.~* Cohort 2: EN001 2.5×10\^6 cells/kg administered intravenously (IV) 2 times at 4 week intervals.
Study: NCT04602936

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo is a substance or treatment which is designed to have no therapeutic value (an inactive compound, i.e. inert, often called a sugar pill).
Study: NCT06289829

Intervention type: DRUG
Group type: OTHER
Intervention: remifentanil of the assigned dose
Description: Ambu Auragain will be inserted after general anesthesia is induced with remimazolam and remifentanil. Each patient will be assigned with a certain dose of remifentanil, according to whether the previous patient's LMA insertion process was successful or not.

Intervention type: DEVICE
Group type: OTHER
Intervention: Ambu Auragain for airway management
Description: Ambu Auragain, a type of laryngeal mask airway, will be inserted into every patient after general anesthesia has been induced.
Study: NCT06413940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofunctional Therapy
Description: Oropharyngeal and tongue exercises : strengthening upper airway muscle 20 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofunctional Therapy
Description: Oropharyngeal and tongue exercises : strengthening upper airway muscle 20 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Respiratory muscle strengthening:inspiratory muscle strengthening by resistive loading of 50% maximum inspiratory pressure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Respiratory muscle strengthening:inspiratory muscle strengthening by resistive loading of 50% maximum inspiratory pressure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Exercise intensity :40%-60% HRmax , 3-5 days/week
Study: NCT05376930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001 Amg
Description: DWP16001 Amg, Tablets, Orally, Once daily
Study: NCT05918211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study: NCT05849766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin Farxiga®
Description: Dapagliflozin 10 mg once daily
Study: NCT04134026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIF-PHI
Description: Drug will be dosed orally three times a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: The drug will be dispensed per the package insert or the country-specific product labeling.
Study: NCT06429982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Steroid five day treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control group
Study: NCT04938986

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IMMUNOSCORE®
Description: recommendation for patient care according to the result of the IMMUNOSCORE®
Study: NCT06368557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CoolMinds: Internet-based cognitive behavioral therapy (iCBT)
Description: The intervention consists of 14 weeks of iCBT, where the main treatment components are psychoeducation, cognitive restructuring, exposure therapy, and relapse prevention. The program comprises eleven sessions for adolescents and ten sessions for parents to be completed simultaneously. The participants will have the opportunity to get therapist feedback during the treatment period, the therapist may spend a maximum of 15 minutes giving feedback per week per participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CoolMinds: Internet-based cognitive behavioral therapy (iCBT)
Description: The intervention consists of 14 weeks of iCBT, where the main treatment components are psychoeducation, cognitive restructuring, exposure therapy, and relapse prevention. The program comprises eleven sessions for adolescents and ten sessions for parents to be completed simultaneously. The participants will have the opportunity to get therapist feedback during the treatment period, the therapist may spend a maximum of 15 minutes giving feedback per week per participant.
Study: NCT05849766

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®
Description: Ramipril 10 mg once daily, carvedilol 6.25 mg twice daily and spironolactone 25 once daily
Study: NCT05858593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality curriculum
Description: Rather than rely on mere exposure to devices, participants in the treatment group will receive a curriculum that integrates the devices into traditional content delivered through the after school program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Virtual reality curriculum
Description: Children will be able to use the same devices but will not have access to a curriculum that integrates the devices with traditional content delivered through the after school program.
Study: NCT05982015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: The RIC procedure consists of five cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed within 24hours after stroke onset, and twice daily for the subsequent 7 days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: The RIC procedure consists of five cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 60 mmHg during the ischemia period. RIC is performed within 24hours after stroke onset, and twice daily for the subsequent 7 days.
Study: NCT05827926

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccine 1
Description: quadrivalent seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccine 1
Description: quadrivalent seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccine 1
Description: quadrivalent seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1083.1
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1083.1
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1083.1
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1083.1
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1083.1
Description: Sterile liquid for injection
Study: NCT05097469

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carbon dioxide laser
Description: 3 consecutive sessions of carbon dioxide laser treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser treatment
Description: 3 consecutive sessions of sham laser treatment
Study: NCT05827926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1083.2
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1083.2
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1083.2
Description: Sterile liquid for injection
Study: NCT06401018

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No noise cancellation and no music playing
Description: In this group of patients, no apparatus was used to prevent noise in the environment, and they were not exposed to any music in the environment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Noise cancelled but not allowed to listen to music
Description: In this group of patients, only noise cancelling was performed during the operation, but no music was played in the environment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Music is played but noise is not cancelled
Description: In this group of patients, ambient noise cancelling was not applied and music, which has been proven to reduce anxiety in studies, was played during surgery.
Study: NCT05593822

Intervention type: PROCEDURE
Group type: OTHER
Intervention: primary percutaneous intervention
Description: percutaneous catheterization through peripheral arteries to coronary arteries
Study: NCT06252506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-dimethyltryptamine (DMT) + harmine
Description: DMT and harmine are the two most abundant chemicals in the Amazonian hallucinogenic plant brew, Ayahuasca, which is used traditionally in spiritual and healing ceremonies. An oral formulation of these two substances will be tested against placebo in the context of an FDG-PET scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-dimethyltryptamine (DMT) + harmine
Description: DMT and harmine are the two most abundant chemicals in the Amazonian hallucinogenic plant brew, Ayahuasca, which is used traditionally in spiritual and healing ceremonies. An oral formulation of these two substances will be tested against placebo in the context of an FDG-PET scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered on one of the study days to compare the effects of DMT and harmine with the effects a placebo administration.
Study: NCT06293443

Intervention type: OTHER
Group type: OTHER
Intervention: Lower extremity unilateral amputee
Description: To evaluate the functionality of lower extremity unilateral amputees, to ensure that the results of the Medicare Functional K Classification System, which provides subjective data for the evaluator, become an objective evaluation method and to determine the functional levels of unilateral amputees; To create an objective data set by applying one-leg standing test, Ten meter walking test, L test, figure-8 walking test, joint range of motion, amputee mobility estimator scale, Houghton scale and joint position sense evaluation tests.
Study: NCT05943028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subanesthetic dose of esketamine
Description: Both groups were given NI-guided propofol-refentanil dual-channel closed-loop target-controlled infusion under general anesthesia with a laryngeal mask/endotracheal intubation. The experimental group (EEG feedback index 36+N) and the control group (EEG feedback index 36) were intravenously injected esketamine 0.2mg∙kg-1 before anesthesia induction, followed by continuous 5μg∙kg-1∙min-1 infusion to maintain anesthesia for 30 minutes, and the maximum cumulative dose allowed was 100mg. In both groups, the infusion was stopped 30 minutes before the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subanesthetic dose of esketamine
Description: Both groups were given NI-guided propofol-refentanil dual-channel closed-loop target-controlled infusion under general anesthesia with a laryngeal mask/endotracheal intubation. The experimental group (EEG feedback index 36+N) and the control group (EEG feedback index 36) were intravenously injected esketamine 0.2mg∙kg-1 before anesthesia induction, followed by continuous 5μg∙kg-1∙min-1 infusion to maintain anesthesia for 30 minutes, and the maximum cumulative dose allowed was 100mg. In both groups, the infusion was stopped 30 minutes before the end of surgery.
Study: NCT05653193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care
Description: Patients starting oral antifungal treatment for chronic pulmonary aspergillosis will be randomised 1:1 to additional interferon-gamma for 3 months or no additional treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antifungals as standard of care
Description: Patients starting oral antifungal treatment for chronic pulmonary aspergillosis will be randomised 1:1 to additional interferon-gamma for 3 months or no additional treatment.
Study: NCT06405958

Intervention type: OTHER
Intervention: gut microbiome
Description: Obtaining new gut microbiome data in organ transplantation

Intervention type: OTHER
Intervention: gut microbiome
Description: Obtaining new gut microbiome data in organ transplantation

Intervention type: OTHER
Intervention: gut microbiome
Description: Obtaining new gut microbiome data in organ transplantation

Intervention type: OTHER
Intervention: gut microbiome
Description: Obtaining new gut microbiome data in organ transplantation

Intervention type: OTHER
Intervention: gut microbiome
Description: Obtaining new gut microbiome data in organ transplantation
Study: NCT05915221

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SMS
Description: Receive SMS
Study: NCT05929157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artesunate-pyronaridine
Description: Pyronaridine and Artesunate are antimalarial agents with a history of clinical use, and Artesunate has been used clinically in combination with other drugs also. The action of Artesunate is a rapid knock down of the parasites, after which, the drug is quickly cleared as it has a short systemic half-life. Pyronaridine is also rapidly effective in the short term but has a long blood half-life thus providing a more sustained schizonticidal effect.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artesunate-pyronaridine
Description: Pyronaridine and Artesunate are antimalarial agents with a history of clinical use, and Artesunate has been used clinically in combination with other drugs also. The action of Artesunate is a rapid knock down of the parasites, after which, the drug is quickly cleared as it has a short systemic half-life. Pyronaridine is also rapidly effective in the short term but has a long blood half-life thus providing a more sustained schizonticidal effect.
Study: NCT04175704

Intervention type: DRUG
Group type: OTHER
Intervention: UB-221
Description: Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution

Intervention type: DRUG
Group type: OTHER
Intervention: UB-221
Description: Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution

Intervention type: DRUG
Group type: OTHER
Intervention: UB-221
Description: Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution

Intervention type: DRUG
Group type: OTHER
Intervention: UB-221
Description: Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution
Study: NCT06046495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLB1004
Description: PLB1004 will be orally self-administered by the patient as a mono-therapy.
Study: NCT05009316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Online-based questionnaires
Study: NCT05827926

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Investigational COVID-19 Vaccine 2
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine 2
Description: Sterile liquid for injection
Study: NCT04781309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: NT-I7 is a recombinant human interleukin-7 fused to a hybrid fragment crystallizable region of a human antibody (hyFc). NT-I6 has a molecular weight of 104 kD. The active moiety of NT-I7 is recombinant human interleukin-7 (rhIL-7), containing human IL-7 (amino acids 4 through 155) and exhibiting all known functions of endogenous human IL-7.
Study: NCT06252506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered on one of the study days to compare the effects of DMT and harmine with the effects a placebo administration.
Study: NCT05458297

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Oral tablet